Our Approach

Our approach to discovery and development of a first-in-class analgesic is based upon a novel approach to pain relief: blocking pain at its source in the peripheral nervous system. In addition, the new drug acts as an analgesic by a defined mechanism of action. The target for the Algomedix drug is located on the endings of sensory nerves that transmit the sensations of pain and hyperalgesia in response to inflammation and injury. Our rational drug discovery approach has resulted in the identification of numerous novel agonists and antagonists. The Algomedix lead compound is protectable from an independent IP position, characterized by drug-like properties and acts by a defined mechanism of action. The next-generation therapeutic we are developing has many factors correlated with commercial success and will be highly differentiated from existing analgesics at launch.